1,1-dimethylethyl α-methylenebenzenebutanoate | 84793-30-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 1,1-dimethylethyl α-methylenebenzenebutanoate
• 英文别名: t-Butyl 2-(2-phenylethyl)acrylate；tert-butyl 2-methylidene-4-phenylbutanoate
• CAS: 84793-30-6
• 化学式: C₁₅H₂₀O₂
• 分子量: 232.323
• InChiKey: RALWXTSRGAULEB-UHFFFAOYSA-N

物化性质

• 沸点：
  314.2±21.0 °C(Predicted)
• 密度：
  0.983±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,1-dimethylethyl α-methylenebenzenebutanoate 在 N-甲基吗啉 、 sodium hydroxide 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三氟乙酸 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 93.5h， 生成 (2S)-4-methylsulfanyl-2-[[(2R)-4-phenyl-2-(sulfanylmethyl)butanoyl]amino]butanoic acid
  参考文献：
  名称：

  Mercaptoacyl aminoacid inhibitors of atriopeptidase. 1. Structure-activity relationship studies of methionine and S-alkylcysteine derivatives

  摘要：

  A broad series of N-(3-mercaptoacyl) amino acid derivatives was evaluated for their ability to inhibit atriopeptidase (neutral endopeptidase, EC 3.4.24.11) in vitro and in vivo. Structural parameters studied were (i) the substituent on the 2-position of the 3-mercaptopropionyl moiety, (ii) the amino acid component, (iii) the S-terminal derivative, and (iv) the C-terminal derivative. Optimum activity was observed for derivatives of methionine and S-alkylcysteines. N-[3-Mercapto-2(S)-[(2-methylphenyl)methyl]-1-oxopropyl]-L-methionine was identified as a highly effective inhibitor of atriopeptidase meriting evaluation as a potential cardiovascular therapeutic agent.

  DOI：

  10.1021/jm00041a026
• 作为产物：
  描述：

  tert-butyl 2-(bromomethyl)acrylate 在 (4,4'-di-tert-butyl-2,2'-dipyridyl)-bis-(2-phenylpyridine(-1H))-iridium(III) hexafluorophosphate 、 N,N-二异丙基乙胺 、 scandium tris(trifluoromethanesulfonate) 作用下， 以 甲醇 、 1,2-二氯乙烷 为溶剂， 反应 3.5h， 生成 1,1-dimethylethyl α-methylenebenzenebutanoate
  参考文献：
  名称：

  吡啶醚的可见光诱导脱氧和烯丙基化/乙烯基化

  摘要：

  在可见光催化下通过未活化醚的脱氧产生烷基自由基是迄今为止尚未解决的挑战。在此，我们报告了通过形成吡啶鎓盐的可见光诱导的吡啶基醚脱氧。生成的苄基自由基进一步与烯丙基/烯基砜反应，以良好至中等的产率提供一系列偶联产物。建议该过程经历一个还原淬火循环，该循环已通过化学、光学和电学实验进行了阐明。

  DOI：

  10.1021/acs.orglett.2c02756

文献信息

• Base-Promoted C–C Bond Activation Enables Radical Allylation with Homoallylic Alcohols
  作者：Maximilian Lübbesmeyer、Emily G. Mackay、Mark A. R. Raycroft、Jonas Elfert、Derek A. Pratt、Armido Studer

  DOI：10.1021/jacs.9b12343

  日期：2020.2.5

  C-radical addition to the double bond of the title reagents and subsequent base-promoted homolytic Cα–Cβ cleavage leads to the formation of the corresponding allylated products along with ketyl radicals that act as single electron reductants to sustain the chain reactions. Substrate scope is documented and the role of base in the C–C bond activation is studied by computation.

  高烯丙醇中的 Cα-Cβ 键可以在碱性条件下被激活，使这些非应变无环系统成为自由基烯丙基化试剂。这种反应性通过光引发（用可见光和/或蓝色 LED）使全氟烷基和分别从全氟烷基碘化物和烷基吡啶鎓盐产生的烷基与高烯丙醇进行烯丙基化反应来举例说明。C-自由基加成到标题试剂的双键和随后的碱促进均裂 Cα-Cβ 裂解导致形成相应的烯丙基化产物以及作为单电子还原剂维持链反应的羰基自由基。记录了底物范围，并通过计算研究了碱在 C-C 键活化中的作用。
• Carboxyalkylcarbonyl aminoacid endopeptidase inhibitors
  申请人：Schering Corporation

  公开号：US05389610A1

  公开（公告）日：1995-02-14

  Carboxyalkylcarbonyl aminoacid inhibitors of endopeptidases of the formula: ##STR1## or pharmaceutically acceptable salt thereof, wherein R.sup.1 is H, alkyl, arylalkyl, aryl or aryloxyalkyl; R.sup.2 is alkyl, alkenyl, alkynyl, alkoxy or alkylthio, wherein the alkyl portion is substituted with 0-3 substituents independently selected from the group consisting of hydroxy, alkoxy, alkoxyalkoxy, alkylthio, aryl, alkoxyalkylthio, arylalkoxy and arylalkylthio; R.sup.3 and R.sup.4 are independently alkyl or arylalkyl; or R.sup.3 and R.sup.4 together with the carbon to which they are attached form an optionally substituted 5-, 6- or 7-membered ring wherein said ring comprises 0 to 1 heteroatoms selected from the group consisting of sulfur and oxygen; R.sup.5 is H, alkyl, alkoxyalkyl, alkylthioalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, arylalkoxyalkyl or arylalkylthioalkyl; R.sup.6 is H, hydroxy, alkoxy, alkyl, arylalkoxy, alkoxyalkyl, alkylthioalkyl, arylalkoxyalkyl, arylalkylthioalkyl, aryl or heteroaryl; R.sup.7 is hydroxy, alkoxy, aryloxy, arylalkoxy, amino, alkylamino or dialkylamino; m is 0 or 1; and n is 0, 1, 2 or 3, use of the compounds, alone or in combination with an ACE inhibitor or an ANF, in the treatment of cardiovascular disorders such as hypertension, congestive heart failure, edema and renal insufficiency, use of the compounds in the treatment of nephrotoxicity and pain conditions, and pharmaceutical compositions containing said compounds are disclosed.

  公开了以下式子的内切蛋白酶的羧基烷基羧酰基氨基酸抑制剂：##STR1##或其药学上可接受的盐，其中R.sup.1为H，烷基，芳基烷基，芳基或芳氧基烷基; R.sup.2为烷基，烯基，炔基，烷氧基或烷硫基，其中烷基部分被0-3个取自羟基，烷氧基，烷氧基烷氧基，烷硫基，芳基，烷氧基烷硫基，芳基烷氧基和芳基烷硫基的基团独立取代; R.sup.3和R.sup.4独立地为烷基或芳基烷基; 或R.sup.3和R.sup.4与它们连接的碳一起形成一个可选取代的5-，6-或7-成员环，其中所述环包括0到1个取自硫和氧的杂原子; R.sup.5为H，烷基，烷氧基烷基，烷硫基烷基，芳基，芳基烷基，杂芳基，杂芳基烷基，芳基烷氧基烷基或芳基烷硫基烷基; R.sup.6为H，羟基，烷氧基，烷基，芳基烷氧基，烷氧基烷基，烷硫基烷基，芳基烷氧基烷基，芳基烷硫基烷基，芳基或杂芳基; R.sup.7为羟基，烷氧基，芳氧基，芳基烷氧基，氨基，烷基氨基或二烷基氨基; m为0或1; n为0, 1, 2或3，本发明公开了这些化合物的使用，单独或与ACE抑制剂或ANF组合使用，用于治疗心血管疾病，如高血压，充血性心力衰竭，水肿和肾功能不全，用于治疗肾毒性和疼痛症状的化合物的使用，以及含有所述化合物的制药组合物。
• Antihypertensive proline derivatives
  申请人：Merck & Co., Inc.

  公开号：US04402969A1

  公开（公告）日：1983-09-06

  The invention relates to urea compounds which are useful as antihypertensives.

  本发明涉及尿素化合物，它们可用作降压药。
• Carboxyalkyl urea compounds and derivatives thereof useful as
  申请人：Merck & Co., Inc.

  公开号：US04866087A1

  公开（公告）日：1989-09-12

  Carboxyalkyl urea compounds and derivatives thereof are disclosed which are useful as angiotensin converting enzyme (ACE) inhibitors and as antihypertensives. These compounds and derivatives are represented by the general formula: ##STR1## An illustrative specie falling within this general formula is: N-(2-carboxy-4-phenylbutyl-N-isopropylaminocarbonyl-L-tryptophan.

  本发明揭示了作为血管紧张素转换酶（ACE）抑制剂和降压剂有用的羧基烷基脲化合物及其衍生物。这些化合物和衍生物由通式所表示： ##STR1## 在这个通式中，一个具体的种类是：N-（2-羧基-4-苯基丁基-N-异丙基氨基羰基-L-色氨酸）。
• Urea compounds as antihypertensives
  申请人：Merck & Co., Inc.

  公开号：EP0061684A1

  公开（公告）日：1982-10-06

  The invention relates to urea compounds of the formula wherein: R is hydrogen, loweralkyl, aralkyl; R1 is alkyl, substituted alkyl, optionally substituted aralkyl and heteroaralkyl; R2 is hydrogen, optionally substituted alkyl; R3 is hydrogen, loweralkyl; R4 is optionally substituted alkyl; or, R3 and R4 may be connected together to form an alkylene bridge or an optionally substituted alkylene bridge containing one sulfur atom and two to three carbon atoms, or an alkylene bridge containing a double bond or a substituted alkylene bridge or an alkylene bridge bearing a benzofusion thereto; and the pharmaceutically acceptable salts thereof, and a process for preparing the same. Those compounds are useful as antihypertensives.

  本发明涉及式中的脲化合物，其中：R是氢、低级烷基、芳烷基；R1是烷基、取代的烷基、任选取代的芳烷基和杂烷基；R2是氢、任选取代的烷基；R3是氢、低级烷基；R4是任选取代的烷基；或者，R3和R4可以连接在一起形成亚烷基桥或任选取代的亚烷基桥，亚烷基桥含有一个硫原子和二至三个碳原子，或者亚烷基桥含有一个双键或取代的亚烷基桥，或者亚烷基桥含有苯并融合物；及其药学上可接受的盐，以及制备这些化合物的工艺。 这些化合物可用作抗高血压药。